A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients 65 Years of Age and Up with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients 65 Years of Age and Up with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)

Protocol No
SWOG-S1318
Principal Investigator
Ehab Atallah
Phase
II
Summary
The purpose of this study is to test any good and bad effects of adding the drug blinatumomab to different doses of standard combination of chemotherapy drugs.
Description
Blinatumomab and either POMP or Dasatinib and Prednisone in Patients >/= 65 With Newly Diagnosed ALL.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: